Chemical formula: C₁₀H₁₅NO Molecular mass: 165.232 g/mol PubChem compound: 7028
Pseudoephedrine interacts in the following cases:
Pseudoephedrine should not be given to patients being treated with monoamine oxidase inhibitors or within 14 days of stopping such treatment.
Pseudoephedrine may enhance the effects of anticholinergic drugs such as tricyclic antidepressants.
Pseudoephedrine may increase the vasoconstrictor effects of ergot alkaloids.
Pseudoephedrine may increase the possibility of arrhythmias in digitalised patients.
The safety of decongestant tablets during pregnancy has not been established but in view of a possible association of foetal abnormalities with first trimester exposure to pseudoephedrine, the use of the product during pregnancy should be avoided.
The safety of decongestant tablets during lactation has not been established. The amounts of pseudoephedrine secreted into breast milk are considered to be too small to be harmful.
No adverse effects known.
Adverse effects may include dry mouth, anxiety, restlessness, tremor, insomnia, tachycardia, cardiac arrhythmias, palpitations, hypertension, nausea, vomiting, headache and occasionally urinary retention in males and skin rashes. Hallucinations have been reported rarely, particularly in children.
Frequency unknown: Severe skin reactions, including acute generalized exanthematous pustulosis (AGEP)
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
